Kan Toriguchi
Papers
1
Total Citations
3
H-Index
1
About
Kan Toriguchi is a translational researcher whose work centers on advancing personalized oncology, with a particular focus on intrahepatic cholangiocarcinoma (ICC)—a devastating liver cancer with a median survival under one year. His most cited study, "Patient-derived organoids for personalized drug screening in intrahepatic cholangiocarcinoma," published in 2020, addresses the urgent need for novel therapies in unresectable ICC. By developing patient-derived organoids, Toriguchi pioneered a platform for real-time, individualized drug sensitivity testing, offering a path beyond the limited efficacy of standard gemcitabine and cisplatin regimens. This work, which has garnered 3 citations, highlights his contribution to bridging the gap between preclinical models and clinical decision-making. Toriguchi’s research underscores the potential of organoid technology to overcome the paucity of targetable mutations in ICC, providing a tangible tool for tailoring treatments to each patient’s tumor biology. His efforts are particularly notable for tackling a cancer where conventional options fall short, positioning him as a key figure in the push toward precision medicine in hepatobiliary malignancies.
Research Focus
Key Achievements
Top Papers
- 1